You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Selective α1-adrenoceptor antagonist (pKi values are 9.0, 8.5 and 8.4 for human α1B, α1A and α1D receptors respectively). Displays antihypertensive activity.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 547.58. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.75 mM||2.43 mL||12.17 mL||24.35 mL|
|3.75 mM||0.49 mL||2.43 mL||4.87 mL|
|7.5 mM||0.24 mL||1.22 mL||2.43 mL|
|37.5 mM||0.05 mL||0.24 mL||0.49 mL|
References are publications that support the biological activity of the product.
Alabaster and Davey (1986) The α1-adrenoceptor antagonist profile of doxazosin: preclinical pharmacology. Br.J.Clin.Pharmacol. 21 9S PMID: 2871857
Kenny et al (1996) Evaluation of the pharmacological selectivity profile of α1 adrenoceptor antagonists at prostatic α1 adrenoceptors: binding functional and in vivo studies. Br.J.Pharmacol. 118 871 PMID: 8799556
Ma et al (2006) Chiral selective effects of doxa. enantiomers on blood pressure and urinaruy bladder pressure in anesthetized rats. Acta Pharmacol.Sinica 27 1423
If you know of a relevant reference for Doxazosin mesylate, please let us know.
View Related Products by Product Action
Keywords: Doxazosin mesylate, Doxazosin mesylate supplier, α1-adrenoceptor, alpha1-adrenoceptor, a1-adrenergic, α1-adrenergic, alpha1-adrenergic, a1-adrenoceptor, antagonists, Receptors, UK33274, UK, 33274, Adrenergic, Alpha-1, 2964, Tocris Bioscience
4 Citations for Doxazosin mesylate
Citations are publications that use Tocris products. Selected citations for Doxazosin mesylate include:
Kahn et al (2016) The anti-hypertensive drug pra. inhibits glioblastoma growth via the PKCδ-dependent inhibition of the AKT pathway. EMBO Mol Med 8 511 PMID: 27138566
Jahchan et al (2013) A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov 3 1364 PMID: 24078773
Diaz et al (2014) Moderate Alcohol Exposure during the Rat Equivalent to the Third Trimester of Human Pregnancy Alters Regulation of GABAA Receptor-Mediated Synaptic Transmission by DA in the Basolateral Amygdala. Front Cell Neurosci 2 46 PMID: 24904907
Cilz et al (2014) DArgic modulation of GABAergic transmission in the entorhinal cortex: concerted roles of α1 adrenoreceptors, inward rectifier K+, and T-type Ca2+ channels. Cereb Cortex 24 3195 PMID: 23843440
Do you know of a great paper that uses Doxazosin mesylate from Tocris? Please let us know.
Reviews for Doxazosin mesylate
There are currently no reviews for this product. Be the first to review Doxazosin mesylate and earn rewards!
Have you used Doxazosin mesylate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.